Eris Lifesciences (ERIS) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 consolidated revenue reached INR 720 crore, up 54% year-over-year, with EBITDA at INR 250 crore, up 47%, driven by acquisitions and organic growth.

• Integration of Biocon and Swiss Parenterals businesses completed ahead of schedule, contributing to revenue and margin expansion.

• Major acquisitions included 19% of Swiss Parenterals and the Indian Branded Formulations business from Biocon Biologics; binding term sheet signed to acquire 100% of Chemman Labs.

• Composite scheme of arrangement for amalgamation of Eris Oaknet Healthcare Private Limited approved.

• Business model evolved to include super specialty segments such as oncology, critical care, and nephrology, with >10% volume growth.

Financial highlights

• Domestic Branded Formulations (DBF) contributed 90% of Q1 revenue, with organic revenue growth of 10%; Q1 DBF revenue: INR 632 crore (nearly 40% growth); EBITDA: INR 225 crore; margin: 36%.

• Swiss Parenterals (exports) Q1 revenue: INR 73 crore; EBITDA: INR 26 crore.

• Gross margin for the quarter at 75%, down 800+ bps due to product mix; EBITDA margin at 34.7%, down 164 bps, offset by fixed cost synergies.

• Q1 PAT: INR 89 crore; cash flow from operations at 70% of EBITDA; cash EPS up 10%.

• Standalone and consolidated financial results for Q1 FY25 were approved, with unmodified auditor opinions.

Outlook and guidance

• FY25 consolidated revenue guidance: INR 3,000+ crore; EBITDA margin: 35%.

• DBF FY25 revenue guidance: INR 2,600+ crore; EBITDA margin: 36-37%.

• Biocon business revenue guided at INR 585 crore (30% EBITDA margin); Swiss Parenterals at INR 330 crore (35% EBITDA margin).

• Capex planned at INR 100-120 crore for hormones, insulins, and MABS; OCF/EBITDA ratio expected at 70-75%.

• Net debt targeted to fall below INR 2,600 crore by FY25 and INR 2,000 crore by FY26.